Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: InforMax Shares Climb 32% Following IPO

This story has been updated from a previous version with closing prices, analyst comments.

NEW YORK, Oct 3 – Shares of Informax (Nasdaq: INMX) jumped more than 32 percent in their first day of trading on the Nasdaq Tuesday, making it the second successful bioinformatics offering since last week.

But some analysts said the recent strong performance in the bioinformatics sector might be short-lived.

Informax, of Rockville, Md., raised $80 million in an offering of 5 million shares that sold for $16 each, at the high-end of the anticipated $14-$16 range. The shares closed up 5 1/4 at 21 1/4.

InforMax’s offering came just two days after Genomica’s (Nasdaq: GNOM) IPO, which raised $122.4 million.

But Rob Olan, research analyst at Chase H&Q, said that even though the IPO market is good for bioinformatics companies right now, the positive momentum could be short-lived.

“I think it’s going to get increasingly difficult if the ones that are currently trading continue to trade down,” said Olan, noting that Compugen (Nasdaq: CGEN), Lion Bioscience (Neuer Markt: LIO; Nasdaq: LEON), and Rosetta Inpharmatics (Nasdaq: RSTA) are all trading off their highs.

He added that newly public bioinformatics companies tend to do well for the first week but then have trouble maintaining their gains.

Bear, Stearns was the lead manager for the InforMax offering. US Bancorp Piper Jaffray and Adams, Harkness & Hill were co-managers.

InforMax’s primary products are its Vector NTI desktop suite and GenoMax enterprise platform for networks of linked computers. This software is used to analyze and interpret genomic, proteomic, and other biomolecular data.

The 172-employee company posted revenues of $10 million and a net loss of $1.3 million in 1999.

Amersham Pharmacia Biotech recently invested $10 million in InforMax and also announced a 20-year strategic collaboration to enhance GenoMax. The deal represents the largest collaboration for InforMax to date.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.